Subgroup analysis revealed that there was no significant difference about Hb response between roxadustat and ESAs in the DD-CKD patient group (OR: 1.27; 95% CI: 0.86–1.87; p = 0.22; Figure 3B and Table 3). This evidence concerns the gene GSTM1 and chronic kidney disease.